secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0001104659-23-124869
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics reports sustained complete response in Phase 1 lymphoma patient at 6 months
--------------------------------------------------------------------------------

- DLBCL patient who failed anti-CD19 CAR T and 3 prior therapies achieved CR at 8 weeks and remains in CR at 6 months after MT-601.
- MT-601 is a multiTAA-specific T cell therapy, non-genetically engineered, well-tolerated without severe CAR T side effects like neurotoxicity.
- Up to 60% of lymphoma patients relapse within one year after CAR T; this patient had relapsed within 90 days yet maintained response.
- Company has enrolled additional patients in APOLLO study to replicate results; City of Hope is the trial site.
- Non-clinical data shows MT-601 can eradicate lymphoma cells resistant to anti-CD19 CAR T in vitro.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923124869/0001104659-23-124869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923124869/tm2332541d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-124869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer